ARWR Arrowhead Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 44

Relative Strength: Rel. Strength: 96

Relative Valuation: Rel. Valuation: 7

Relative Profitability: Rel. Profitability: 30

EPS in 2026 (TTM): -$2.25

Last Report Period Date: Jun 30, 2026

Based on the company's latest reports for June 2026, the current 12-month EPS is -$2.25. Arrowhead Pharmaceuticals's earnings per share in 2025 was reported at -$0.01, marking a rise from -$5 in 2024. In the quarterly report ending on Jun 30, 2026, ARWR's earnings per share amounted to -$1.36.

ARWR earnings history

Historical annual and quarterly earnings per share (EPS) data for Arrowhead Pharmaceuticals

EPS (TTM)

-$2.25

EPS Growth YoY (Quarterly)

-7.9%

EPS (Quarterly)

-$1.36

EPS Growth (Quarterly)

-46.2%

Arrowhead Pharmaceuticals had an yealy earnings per share of -$0.01, showing a rise of 99.8% from -$5 recorded in 2024. The quarterly earnings per share for the period ending Jun 30, 2026, was -$1.36, showing a 7.9% decline compared to the same quarter last year. The trailing twelve months EPS for ARWR is -$2.25 as of June 2026. Arrowhead Pharmaceuticals's full-year EPS for 2024 was -$5, a 160.4% decline compared to the previous year.

ARWR EPS vs price chart

ARWR EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-7.9%

EPS growth YoY

99.8%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Over the past 12 months, Arrowhead Pharmaceuticals has recorded an earnings per share growth rate of -7.9% (YoY, quarterly).

ARWR Earnings Waterfall

Breakdown of revenue, profit and net income for Arrowhead Pharmaceuticals

ARWR Earnings vs Peers

What are the earnings of ARWR compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
LGND Ligand Pharmaceuticals Inc - Class B	28.43	3,027.3%	N/A	N/A
JNJ Johnson & Johnson	30.96	90.6%	17.7%	14.8%
ALNY Alnylam Pharmaceuticals Inc	38.72	209.6%	N/A	N/A
INO Inovio Pharmaceuticals Inc	N/A	54.2%	N/A	N/A
MRNA Moderna Inc	N/A	21.8%	N/A	N/A
ARWR Arrowhead Pharmaceuticals Inc	N/A	99.8%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.